1 February 2022
NZ pigs possible key to treating Parkinson's

MARKET CAPITALISATION
$15601400
LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions such as Parkinson’s disease, obesity and migraine.
Our product candidates leverage the potential of cells and their receptors to address serious conditions that have an unmet need for effective treatments.
We are listed on both the Australian Securities Exchange (ASX:LCT) and the international OTCQB (LVCLY). Share registry services are provided by Automic.
1 February 2022
25 January 2022
"Of all the places in the world where you thought a cure for Parkinson’s disease might be found, the remote sub-Antar...